CureVac N.V. logo

CVAC

CureVac N.V.

$13.21

Earnings Summary

Revenue
$24.37Mn
Net Profits
$-15.09Mn
Net Profit Margins
-61.93%

Highlights

Revenue:

CureVac N.V.’s revenue jumped 143% since last year same period to $24.37Mn in the Q1 2022. On a quarterly growth basis, CureVac N.V. has generated -40.88% fall in its revenue since last 3-months.

Net Profits:

CureVac N.V.’s net profit jumped 86.73% since last year same period to $-15.09Mn in the Q1 2022. On a quarterly growth basis, CureVac N.V. has generated -679.6% fall in its net profits since last 3-months.

Net Profit Margins:

CureVac N.V.’s net profit margin jumped 94.54% since last year same period to -61.93% in the Q1 2022. On a quarterly growth basis, CureVac N.V. has generated -1218.63% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the CureVac N.V. post its latest quarter earnings

EPS Estimate Current Year
-0.57

Highlights

EPS Estimate Current Year:

CureVac N.V.’s earning per share (EPS) estimates for the current year stand at -0.57.

Key Ratios

Key ratios of the CureVac N.V. post its Q1 2022 earnings

Earning Per Share (EPS)
-0.08
Return on Assets (ROA)
-0.49
Return on Equity (ROE)
-0.45
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

CureVac N.V.’s earning per share (EPS) jumped 75.76% since last year same period to -0.08 in the Q1 2022. This indicates that the CureVac N.V. has generated 75.76% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. CureVac N.V.’s return on assets (ROA) stands at -0.49.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. CureVac N.V.’s return on equity (ROE) stands at -0.45.

Dividend Per Share (DPS):

CureVac N.V. declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-03-31
-0.57
-0.08
85.96%

Company Information

CureVac N.V. operates as a global clinical-stage biopharmaceutical company. The Company focuses on developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. CureVac serves customers worldwide.

Organisation
CureVac N.V.
Headquarters
Tuebingen, Baden Wuerttemberg, Germany
Employees
505
Industry
Health Technology